Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | SMO | Q99835 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209503 | 0.84 | ALDH1A1 (0.43) | ARCYP1A2SMOLMNASMN1; SMN2 | |
| SCHEMBL1999559 | 0.77 | SMO (0.65) | ARCYP1A2SMOCYP2D6LMNA | |
| SCHEMBL2001301 | 0.76 | P2RX7 (0.42) | CYP1A2SMOLMNASMN1; SMN2NPC1 | |
| SCHEMBL2001193 | 0.74 | SMO (0.65) | ARCYP1A2SMOCYP2D6LMNA | |
| SCHEMBL12775834 | 0.72 | AR (0.54) | ARCYP1A2SMOLMNAMEN1 | |
| SCHEMBL19661666 | 0.71 | CYP1A2 (0.53) | ARCYP1A2SMOCYP2D6LMNA | |
| SCHEMBL1999485 | 0.71 | NR3C2 (0.40) | CYP1A2LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1194345 | 0.70 | NPC1 (0.56) | ARNPC1RAB9A | |
| SCHEMBL1999531 | 0.68 | RECQL (0.55) | ARCYP1A2SMOLMNAMEN1 | |
| SCHEMBL19120569 | 0.66 | CYP1A2 (0.50) | ARCYP1A2SMOCYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960413-B2 | Pyrazole compounds | MERCK PATENT GMBH (DE) | 2011-06-14 | — | — | US | disclosed |
| US-20060276650-A1 | Pyrazole compounds | MERCK PATENT GMBH (DE) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276650-A1 | Pyrazole compounds | HTR1D, HTR1A, HTR3A | AR 483/4885CYP1A2 264/4885SMO 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.